PECAM1 and glioblastoma: Patients with GBM expressing endothelial marker CD31 above the median (60.4 mm-2) experienced significantly longer estimated median PFS than patients with CD31 bellow this value (64 vs. 43 days, respectively; P = 0.041, long-rank test).